---
title: Efficacy, Safety, Tolerability of Pegaptanib Sodium (Macugen) in Filipino Patients With Neovascular Age Related Macular Degeneration.
nct_id: NCT00820742
overall_status: WITHDRAWN
sponsor: Pfizer
study_type: OBSERVATIONAL
primary_condition: Neovascular Age-related Macular Degeneration
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00820742.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00820742"
ct_last_update_post_date: 2015-03-05
last_seen_at: "2026-05-12T07:03:57.585Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Efficacy, Safety, Tolerability of Pegaptanib Sodium (Macugen) in Filipino Patients With Neovascular Age Related Macular Degeneration.

**Official Title:** The Efficacy, Safety, and Tolerability of Pegaptanib Sodium in Filipino Patients With Neovascular Age-related Macular Degeneration: A Post Marketing Surveillance Study.

**NCT ID:** [NCT00820742](https://clinicaltrials.gov/study/NCT00820742)

## Key Facts

- **Status:** WITHDRAWN
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 0
- **Lead Sponsor:** Pfizer
- **Conditions:** Neovascular Age-related Macular Degeneration
- **Start Date:** 2008-02
- **Completion Date:** 2009-05
- **CT.gov Last Update:** 2015-03-05

## Brief Summary

An open label, non-comparative, multicenter, non-interventional, post marketing surveillance study to evaluate the overall safety and tolerability of pegaptanib sodium(Macugen) in the treatment of Filipino patients with neovascular age-related macular degeneration based on incidence of adverse events and to evaluate the efficacy based on visual acuity, and the patient's and physician's overall satisfaction with tolerability and efficacy.

## Detailed Description

Open-label, non-comparative, non-interventional study

## Eligibility

- **Minimum age:** 50 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Must have at least one eye which was diagnosed with neovascular degeneration

Exclusion Criteria:

* Presence of other causes of choroidal neovascularization, including pathologic myopia (spherical equivalent of -8 diopters or more negative, or axial length of 25mm or more), ocular histoplasmosis syndrome, angioid streaks, choroidal rupture, multifocal choroiditis
```

## Arms

- **Phase IV Post Marketing Surveillance Study** — Open-label, observational study

## Interventions

- **Macugen** (DRUG) — Intravitreous injection of Pegaptanib Sodium 3.47 mg/mL solution every 6 weeks

## Primary Outcomes

- **Incidence of adverse events and serious adverse events** _(time frame: 12 months)_

## Secondary Outcomes

- **Mean change in visual acuity in the study eye at 6 months from baseline** _(time frame: 6 months)_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00820742.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00820742*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*